Teresa Bitetti, President of Takeda Pharmaceutical Company Limited's Global Oncology Business Unit, filed a Form 144 notice on October 30, 2026, disclosing a proposed sale of 46,609 American Depositary Shares on NYSE.

Key Highlights

  • Proposed sale: 46,609 American Depositary Shares (ADSs) with an aggregate market value of $940,103.53, according to the filing.
  • Approximate sale date: November 1, 2026, through Interactive Brokers LLC, One Pickwick Plaza, Greenwich, CT 06830.
  • Source of shares: The securities were acquired on July 30, 2024, via Restricted Stock Unit Awards that vested on that date, as compensation from Takeda Pharmaceutical Company Limited.
  • Shares outstanding: The filing lists 198,318,946 ADS units outstanding at time of notice.
  • Prior three-month sale: Bitetti sold 50,012 ADSs on August 10, 2026, for gross proceeds of $855,205.20; the filing states that sale "was conducted in order to satisfy tax obligations in connection with share vesting effective July 13, 2026."
  • Signing authority: The notice was signed by Kate Huleatt, by power of attorney for Teresa Bitetti.

Details of the Proposed ADS Sale by Takeda's Global Oncology President

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Teresa Bitetti, identified as President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Limited (NYSE:TAK), intends to sell 46,609 ADSs with a stated aggregate market value of $940,103.53. The proposed sale is expected to occur on or around November 1, 2026, and is to be executed through Interactive Brokers LLC.

The filing discloses that the shares to be sold were acquired on July 30, 2024, through Restricted Stock Unit Awards that vested on that date, with the nature of payment listed as compensation. The securities represent a portion of the 198,318,946 ADS units the filing identifies as outstanding. Takeda Pharmaceutical Company Limited is identified as the issuer, with SEC File Number 001-38757 and its principal address in Chuo-ku, Tokyo, Japan.

With respect to activity in the prior three months, the filing reports that Bitetti sold 50,012 ADSs on August 10, 2026, generating gross proceeds of $855,205.20. The filing includes a remark stating that prior sale "was conducted in order to satisfy tax obligations in connection with share vesting effective July 13, 2026." No similar explanatory remark is provided for the currently proposed sale.

What Was Disclosed

The Form 144 notice discloses Teresa Bitetti's proposed sale of 46,609 Takeda ADSs valued at $940,103.53, acquired through vested RSU awards in July 2024, with an approximate sale date of November 1, 2026, via Interactive Brokers LLC on NYSE.